Both psoriasis and HS are chronic inflammatory skin disease and with many comorbidities and the best therapeutical choice is represented by biologics. The problem of biologics is the highimpact on economical conditions. The advent of biosimilars has been a great advantage due to the lower costs . They have proved to have the same efficacy and safety profile of the originators and do represent an important therapeutica option.
SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis / Di Cesare A.; Tronconi G.; Fastame T.M.; Rosi E.; Pescitelli L.; Ricceri F.; Prignano F.. - In: DERMATOLOGIC THERAPY. - ISSN 1396-0296. - ELETTRONICO. - 33:(2020), pp. 1-1. [10.1111/dth.13435]
SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis
Prignano F.
2020
Abstract
Both psoriasis and HS are chronic inflammatory skin disease and with many comorbidities and the best therapeutical choice is represented by biologics. The problem of biologics is the highimpact on economical conditions. The advent of biosimilars has been a great advantage due to the lower costs . They have proved to have the same efficacy and safety profile of the originators and do represent an important therapeutica option.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Dermatologic Therapy - 2020 - Di Cesare - SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
424.07 kB
Formato
Adobe PDF
|
424.07 kB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
